Female Infertility – Pipeline Review, H1 2012

Document Sample
Female Infertility – Pipeline Review, H1 2012 Powered By Docstoc
					                 Female Infertility – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1817IDB
                                                                                           Publication Date: February 2012




Female Infertility – Pipeline Review, H1 2012                                              GMDHC1817IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Female Infertility – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 10
    List of Figures .............................................................................................................................................................................. 11
Introduction....................................................................................................................................................................................... 12
    Global Markets Direct Report Coverage ...................................................................................................................................... 12
Female Infertility Overview ............................................................................................................................................................... 13
Therapeutics Development............................................................................................................................................................... 14
    An Overview of Pipeline Products for Female Infertility ............................................................................................................... 14
Female Infertility Therapeutics under Development by Companies ................................................................................................. 16
Female Infertility Therapeutics under Investigation by Universities/Institutes ................................................................................... 19
Late Stage Products ......................................................................................................................................................................... 22
    Comparative Analysis .................................................................................................................................................................. 22
Mid Clinical Stage Products.............................................................................................................................................................. 23
    Comparative Analysis .................................................................................................................................................................. 23
Early Clinical Stage Products ........................................................................................................................................................... 24
    Comparative Analysis .................................................................................................................................................................. 24
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 25
    Comparative Analysis .................................................................................................................................................................. 25
Female Infertility Therapeutics – Products under Development by Companies ............................................................................... 26
Female Infertility Therapeutics – Products under Investigation by Universities/Institutes ................................................................. 28
Companies Involved in Female Infertility Therapeutics Development .............................................................................................. 29
    Abbott Laboratories ..................................................................................................................................................................... 29
    Vyteris, Inc. .................................................................................................................................................................................. 30
    Watson Pharmaceuticals, Inc. ..................................................................................................................................................... 31
    Merck & Co., Inc. ......................................................................................................................................................................... 32
    Euroscreen S.A. .......................................................................................................................................................................... 33
    Takeda Pharmaceutical Company Limited .................................................................................................................................. 34
    ASKA Pharmaceutical Co., Ltd .................................................................................................................................................... 35
    Astellas Pharma Inc..................................................................................................................................................................... 36
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 37
    Kissei Pharmaceutical Co., Ltd. ................................................................................................................................................... 38
    Teva Pharmaceutical Industries Limited ...................................................................................................................................... 39
    Zydus Cadila Healthcare Limited ................................................................................................................................................. 40
    Pantec Biosolutions AG ............................................................................................................................................................... 41
    Merck KGaA ................................................................................................................................................................................ 42
    Access Pharmaceuticals, Inc. ...................................................................................................................................................... 43
    Addex Pharmaceuticals ............................................................................................................................................................... 44
    AEterna Zentaris Inc. ................................................................................................................................................................... 45
    Soligenix, Inc. .............................................................................................................................................................................. 46
    Repros Therapeutics Inc. ............................................................................................................................................................ 47
    Protalix BioTherapeutics, Inc. ...................................................................................................................................................... 48
    Glycotope GmbH ......................................................................................................................................................................... 49



Female Infertility – Pipeline Review, H1 2012                                                                                               GMDHC1817IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Female Infertility – Pipeline Review, H1 2012




    Peptron, Inc. ................................................................................................................................................................................ 50
    Meditrina Pharmaceuticals, Inc.................................................................................................................................................... 51
    PregLem SA ................................................................................................................................................................................ 52
    Ferring Pharmaceuticals, Inc. ...................................................................................................................................................... 53
    Isifer AB ....................................................................................................................................................................................... 54
Female Infertility – Therapeutics Assessment .................................................................................................................................. 55
    Assessment by Monotherapy Products ....................................................................................................................................... 55
    Assessment by Combination Products ........................................................................................................................................ 56
    Assessment by Route of Administration ...................................................................................................................................... 57
    Assessment by Molecule Type .................................................................................................................................................... 59
Drug Profiles..................................................................................................................................................................................... 61
    AEZS-115 - Drug Profile .............................................................................................................................................................. 61
        Product Description................................................................................................................................................................. 61
        Mechanism of Action ............................................................................................................................................................... 61
        R&D Progress ......................................................................................................................................................................... 61
    TAK-385 - Drug Profile ................................................................................................................................................................ 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Anastrozole - Drug Profile ........................................................................................................................................................... 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    Elagolix - Drug Profile .................................................................................................................................................................. 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    ADX68692 - Drug Profile ............................................................................................................................................................. 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    GnRH Antagonists - Drug Profile ................................................................................................................................................. 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    GnRH Patch - Drug Profile .......................................................................................................................................................... 68
        Product Description................................................................................................................................................................. 68
        Mechanism of Action ............................................................................................................................................................... 68
        R&D Progress ......................................................................................................................................................................... 68
    Proellex - Drug Profile ................................................................................................................................................................. 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    Recombinant Hormones For Ovulation Induction - Drug Profile .................................................................................................. 71


Female Infertility – Pipeline Review, H1 2012                                                                                               GMDHC1817IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(3)
Female Infertility – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 71
        Mechanism of Action ............................................................................................................................................................... 71
        R&D Progress ......................................................................................................................................................................... 71
    LPM Leuprolide - Drug Profile ..................................................................................................................................................... 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    PRX-111 - Drug Profile ................................................................................................................................................................ 74
        Product Description................................................................................................................................................................. 74
        Mechanism of Action ............................................................................................................................................................... 74
        R&D Progress ......................................................................................................................................................................... 74
    Fertility Hormone - Drug Profile ................................................................................................................................................... 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    Drugs For Prostate Cancer & Endometriosis - Drug Profile ......................................................................................................... 76
        Product Description................................................................................................................................................................. 76
        Mechanism of Action ............................................................................................................................................................... 76
        R&D Progress ......................................................................................................................................................................... 76
    JR-041 - Drug Profile ................................................................................................................................................................... 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress .........................................
				
DOCUMENT INFO
Description: Female Infertility - Pipeline Review, H1 2012', provides an overview of the Female Infertility therapeutic pipeline. This report provides information on the therapeutic development for Female Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Infertility. 'Female Infertility - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries